ARTICLE | Company News
Akeso, Merck deal
December 21, 2015 8:00 AM UTC
Akeso granted Merck exclusive, worldwide rights to develop and commercialize AK-107. The product is an immune checkpoint blocking antibody in preclinical development to treat cancer. Akeso will recei...